TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19948978

Group type: EXPERIMENTAL
Intervention: HbA(1c) >8%
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: Each 1% increase in HbA(1c)
Number of subjects: 1255

Group type: COMPARATOR
Intervention: HbA(1c) < or =6%
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: HbA(1c) levels
Number of subjects: 1255
Study: 17845684

Group type: EXPERIMENTAL
Intervention: Serotonin agonists (cisapride and mosapride)
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: Mosapride
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 789

Group type: COMPARATOR
Intervention: Control agents (dopamine antagonists: metoclopramide and domperidone; opiate agonist: trimebutine)
Number of subjects: 789
Study: 15493405

Group type: EXPERIMENTAL
Intervention: Graphosyllabic instruction
Number of subjects: 3

Group type: COMPARATOR
Intervention: Whole-word instruction
Number of subjects: 3

Group type: COMPARATOR
Intervention: No special instruction (control group)
Number of subjects: 3
Study: 11219562

Group type: COMPARATOR
Intervention: Usual care (physician-delivered advice and follow-up)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Telephonic counseling (6 computer-assisted sessions by office nurses and telephone counselors)
Number of subjects: 233
Study: 11360574

Group type: EXPERIMENTAL
Intervention: Fufang prednisone group (mixture of prednisone and EB)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Prednisone group (control)
Number of subjects: 65

Group type: COMPARATOR
Intervention: CORT control group (experimental model)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: EB group (experimental research)
Number of subjects: 65
Study: 7836550

Group type: EXPERIMENTAL
Intervention: Lovastatin (40 mg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 29581220

Group type: EXPERIMENTAL
Intervention: Vegan-donor fecal microbiota transplantation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Autologous fecal microbiota transplantation
Number of subjects: 20
Study: 27622957

Group type: EXPERIMENTAL
Intervention: Laser therapy
Number of subjects: 58

Group type: COMPARATOR
Intervention: Occlusal stabilization splint
Number of subjects: 58
Study: 24481828

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided leukocyte-rich PRP injection with standardized eccentric exercises
Number of subjects: 23

Group type: COMPARATOR
Intervention: Ultrasound-guided dry needling (DN) with standardized eccentric exercises
Number of subjects: 23
Study: 23250159

Group type: COMPARATOR
Intervention: Filtek Silorane composite resin only (Group 1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Preimpregnated glass fibers placed at gingival third (Group 2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Preimpregnated glass fibers placed at middle third (Group 3)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Preimpregnated glass fibers placed at occlusal third (Group 4)
Number of subjects: 60
Study: 20140683

Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 24
Study: 18974704

Group type: EXPERIMENTAL
Intervention: Amputation of the ischemic limb
Number of subjects: 40
Study: 16568436

Group type: EXPERIMENTAL
Intervention: T2* multiecho MRI
Number of subjects: 53
Study: 14605158

Group type: EXPERIMENTAL
Intervention: Indirect immunofluorescence assay (IFA)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Shell vial culture (SVC)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Urine sample
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Throat swab
Number of subjects: 62
Study: 11029730

Group type: EXPERIMENTAL
Intervention: Functional appliances (Fränkel function regulators or Harvold activators)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated subjects
Number of subjects: 0
Study: 8742120

Group type: EXPERIMENTAL
Intervention: 4 IU hGH with TPN
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: 8 IU hGH with HPN
Number of subjects: 216

Group type: COMPARATOR
Intervention: TPN
Number of subjects: 216

Group type: COMPARATOR
Intervention: HPN
Number of subjects: 216
Study: 1395888

Group type: EXPERIMENTAL
Intervention: Intrauterine and pelvic irrigation with ampicillin
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Systemic use of penicillin+gentamycin
Number of subjects: 217

Group type: COMPARATOR
Intervention: Control group: no antibiotics given
Number of subjects: 217
Study: 4049610

Group type: EXPERIMENTAL
Intervention: No-catheter postoperative management
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Hydraulic self-dilatation of the urethra
Number of subjects: 62
Study: 31505519

Group type: EXPERIMENTAL
Intervention: Escitalopram (SRI) treatment
Number of subjects: 65
Study: 28933625

Group type: EXPERIMENTAL
Intervention: IIV4 (quadrivalent split‐virion inactivated influenza vaccine)
Number of subjects: 300

Group type: COMPARATOR
Intervention: IIV3 (licensed split‐virion trivalent inactivated influenza vaccine)
Number of subjects: 300
Study: 27349154

Group type: COMPARATOR
Intervention: Cerebellar a-tDCS
Number of subjects: 59

Group type: COMPARATOR
Intervention: M1a-tDCS
Number of subjects: 59
Study: 26054175

Group type: EXPERIMENTAL
Intervention: Orbit White chewing gum (chewed four times per day for 15 minutes each)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No gum (control group)
Number of subjects: 0
Study: 22698563

Group type: EXPERIMENTAL
Intervention: MECC
Number of subjects: 40

Group type: COMPARATOR
Intervention: CECC
Number of subjects: 40
Study: 20602068

Group type: EXPERIMENTAL
Intervention: Cuídate program
Number of subjects: 708

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 708
Study: 17365767

Group type: EXPERIMENTAL
Intervention: Active nicotine patches
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 16
Study: 16295308

Group type: EXPERIMENTAL
Intervention: Service-learning project in maternal-infant health course
Number of subjects: 0
Study: 12047056

Group type: EXPERIMENTAL
Intervention: Performance predictions based on retention estimates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anticipated test delay (15 min or 2 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual differences in performance
Number of subjects: 0
Study: 9862513

Group type: EXPERIMENTAL
Intervention: 120FEC with early primary G-CSF (days 4 to 13)
Number of subjects: 66

Group type: COMPARATOR
Intervention: 60FEC without G-CSF
Number of subjects: 66
Study: 8543644

Group type: EXPERIMENTAL
Intervention: Aspirin (50 ml solution, concentration 3 mg/ml)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Distilled water (placebo)
Number of subjects: 10
Study: 2093112

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins at doses of 1 g/Kg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Randomized therapy (Control)
Number of subjects: 20
Study: 272413

Group type: EXPERIMENTAL
Intervention: Mouthrinsing with sodium‐p‐toluene sulfonchloramide (chloramine‐T)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Toothbrushing with chloramine‐T
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Irrigation with Lugol's solution
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 100
Study: 30997164

Group type: EXPERIMENTAL
Intervention: HMS BAB training
Number of subjects: 331

Group type: COMPARATOR
Intervention: Standard practices
Number of subjects: 331
Study: 29256465

Group type: EXPERIMENTAL
Intervention: 100 ml of 0.9% saline solution
Number of subjects: 2

Group type: COMPARATOR
Intervention: 250 ml of 0.9% saline solution
Number of subjects: 2
Study: 26330593

Group type: EXPERIMENTAL
Intervention: Portal and joint infiltration with levo-bupivacaine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Wrist block with levo-bupivacaine
Number of subjects: 66
Study: 23148500

Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg/day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Valsartan (80-320 mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both treatments (Amlodipine and Valsartan)
Number of subjects: 50
Study: 21191380

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 19654333

Group type: EXPERIMENTAL
Intervention: Sapropterin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16984797

Group type: EXPERIMENTAL
Intervention: Antenatal betamethasone treatment (single course)
Number of subjects: 43
Study: 14697925

Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg twice daily
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cyclosporine with itraconazole
Number of subjects: 8

Group type: COMPARATOR
Intervention: Cyclosporine alone
Number of subjects: 8
Study: 11099808

Group type: EXPERIMENTAL
Intervention: Negative patterning (NP) group with letter stimuli (C, N, M, J) reinforced by shock when alone but not in compound.
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group with the same paired‐unpaired sequence but with additional nonreinforced letters (X and H).
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Negative patterning (NP) group with one pair of letters reinforced as elements but not in compound.
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group with the same paired‐unpaired sequence but with a compound containing two different letters from the reinforced ones.
Number of subjects: 2
Study: 9750603

Group type: EXPERIMENTAL
Intervention: Emla cream + 50 vol% nitrous oxide in oxygen
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo + 100 vol% oxygen
Number of subjects: 75
Study: 8456888

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol therapy
Number of subjects: 223

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study: 3524093

Group type: EXPERIMENTAL
Intervention: Occlusal adjustment (with 19 patients also receiving splint therapy)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo (mock adjustment)
Number of subjects: 91
Study: 28701596

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ketofol
Number of subjects: 60
Study: 26165396

Group type: EXPERIMENTAL
Intervention: Behavioural intervention (diet and physical activity), delivered once a week through eight health trainer-led sessions.
Number of subjects: 1555

Group type: COMPARATOR
Intervention: Standard antenatal care (control group).
Number of subjects: 1555

Group type: EXPERIMENTAL
Intervention: Behavioural intervention (diet and physical activity).
Number of subjects: 1555
Study: 24995901

Group type: EXPERIMENTAL
Intervention: Auditory electrical stimulation (AES)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (PES)
Number of subjects: 44
Study: 20041881

Group type: EXPERIMENTAL
Intervention: Angina Plan (AP)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 218
Study: 19745641

Group type: EXPERIMENTAL
Intervention: 0.25 mg single dose of triazolam
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 0.5 mg divided between 2 equal doses for 60 minutes
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 0.75 mg divided among 3 doses for 90 minutes
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 16524479

Group type: EXPERIMENTAL
Intervention: Welfare rights advice
Number of subjects: 126
Study: 15269853

Group type: EXPERIMENTAL
Intervention: Coronal preflaring using size 25# and 20# ProFile.06 taper NiTi rotary instrument
Number of subjects: 48

Group type: COMPARATOR
Intervention: No intervention (Group 1)
Number of subjects: 48
Study: 11730260

Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg
Number of subjects: 184

Group type: COMPARATOR
Intervention: Risedronate (combined data from both studies)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Risedronate 2.5 mg
Number of subjects: 184
Study: 9150326

Group type: EXPERIMENTAL
Intervention: L-ASA (90 mg x mL(‐1))
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (glycine, 30 mg x mL(‐1))
Number of subjects: 12
Study: 7716955

Group type: EXPERIMENTAL
Intervention: Olicard 40 (isosorbide mononitrate)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Cardonit 40 (isosorbide dinitrate)
Number of subjects: 52
Study: 2465581

Group type: EXPERIMENTAL
Intervention: Videotape intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 30048027

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (64 mmol daily)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study: 26043561

Group type: EXPERIMENTAL
Intervention: Syndrome differentiation based acupuncture (Group A)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Ordinary acupuncture (Group B)
Number of subjects: 70
Study: 22258186

Group type: EXPERIMENTAL
Intervention: Tagger's hybrid technique
Number of subjects: 70

Group type: COMPARATOR
Intervention: Lateral condensation technique
Number of subjects: 70

Group type: COMPARATOR
Intervention: Thermafil system
Number of subjects: 70
Study: 21799810

Group type: EXPERIMENTAL
Intervention: PEV3B
Number of subjects: 50

Group type: COMPARATOR
Intervention: Inflexal®V
Number of subjects: 50
Study: 19031076

Group type: EXPERIMENTAL
Intervention: Chloroquine treatment (25 mg/kg body weight, orally on three consecutive days)
Number of subjects: 40
Study: 17073869

Group type: EXPERIMENTAL
Intervention: Moving to a sunny subtropical climate (Gran Canary) for 4 weeks
Number of subjects: 56

Group type: COMPARATOR
Intervention: Home in Norway (control group)
Number of subjects: 56
Study: 15327407

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 1046

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1046
Study: 11194533

Group type: EXPERIMENTAL
Intervention: Dietary diacylglycerol (DG) emulsion
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 44 g-DG emulsion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Triacylglycerol (TG) emulsion
Number of subjects: 40
Study: 9258482

Group type: EXPERIMENTAL
Intervention: Heparin 50 IU/kg
Number of subjects: 366

Group type: COMPARATOR
Intervention: Heparin 100 IU/kg
Number of subjects: 366
Study: 7981758

Group type: EXPERIMENTAL
Intervention: HLA class II alleles (specifically DR3 and DR4 haplotypes)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: HLA class II alleles (specifically DRB1*1402)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: DR-DQ DR4 haplotypes bearing DQB1*0302
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: DRB1 allele
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Asp-57 in the HLA-DQ beta chain
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: DRB1 and DQB1
Number of subjects: 42
Study: 3300583

Group type: EXPERIMENTAL
Intervention: Membrane oxygenator and dipyridamole
Number of subjects: 44

Group type: COMPARATOR
Intervention: Bubble oxygenator and no dipyridamole
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Bubble oxygenator with dipyridamole
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Membrane oxygenator without dipyridamole
Number of subjects: 44
Study: 30185733

Group type: COMPARATOR
Intervention: Nusinersen (Spinraza®)
Number of subjects: 0
Study: 24617349

Group type: EXPERIMENTAL
Intervention: Isoflavone-rich soy protein (25 grams daily, 91 mg of aglycone weight isoflavones: 52 mg genistein, 36 mg daidzein, 3 mg glycitein)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Isoflavone-rich soy protein
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Plasma isoflavonoid levels
Number of subjects: 350

Group type: COMPARATOR
Intervention: Milk protein-matched placebo
Number of subjects: 350
Study: 23754821

Group type: EXPERIMENTAL
Intervention: Computer-assisted SSRO
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional SSRO
Number of subjects: 8
Study: 19896204

Group type: EXPERIMENTAL
Intervention: Fluvoxamine + weak variable magnetic field (VIOFOR JPS device)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fluvoxamine + placebo (VIOFOR JPS device in placebo mode)
Number of subjects: 30
Study: 18549459

Group type: EXPERIMENTAL
Intervention: Ibuprofen-Phosphatidylcholine (PC)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 125
Study: 21146375

Group type: EXPERIMENTAL
Intervention: Early improvement in positive affect during the first week of treatment
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Early change in negative emotions
Number of subjects: 49
Study: 16195989

Group type: EXPERIMENTAL
Intervention: Chronic aerobic exercise (athletes)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Regular insulin iontophoresis (0.1 ml Humulin R 100 IU/ml diluted 1/10 with 0.9 % saline)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ischemia response
Number of subjects: 20
Study: 11805506

Group type: EXPERIMENTAL
Intervention: Topical netilmicin
Number of subjects: 209

Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 209

Group type: COMPARATOR
Intervention: Topical netilmicin and Gentamicin
Number of subjects: 209
Study: 9809091

Group type: EXPERIMENTAL
Intervention: Cutting point needles (50-mm-long 25G Quincke and 25-mm-long 26G Atraucan)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Pencil point needles (37-mm-long 27G Whitacre and 35-mm-long 24G Sprotte)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: All needles
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Pencil point needles
Number of subjects: 200
Study: 8573661

Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Sertraline 100 mg
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Sertraline 200 mg
Number of subjects: 369

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 369
Study: 2667209

Group type: EXPERIMENTAL
Intervention: Campath-1M (10-day course postoperatively) + high-dose cyclosporine (17 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (high-dose cyclosporine alone)
Number of subjects: 0
Study: 28687

Group type: EXPERIMENTAL
Intervention: H 87/07
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 11445789

Group type: EXPERIMENTAL
Intervention: Oral dexamethasone (DEX) 0.6 mg/kg, maximum 16 mg for 2 days
Number of subjects: 533

Group type: COMPARATOR
Intervention: Oral prednisone (PRED) 2 mg/kg, maximum 60 mg for 5 days
Number of subjects: 533
Study: 31171963

Group type: EXPERIMENTAL
Intervention: Virtual reality technology (5-min exposure to the operating room)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no virtual reality exposure)
Number of subjects: 40
Study: 28945675

Group type: EXPERIMENTAL
Intervention: Taurine (40 mg·kg body mass) in noncaffeine consumers
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Taurine (40 mg·kg body mass) in caffeine consumers deprived of caffeine
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Taurine (40 mg·kg body mass) in noncaffeine consumers (isometric)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Taurine (40 mg·kg body mass) in caffeine consumers deprived of caffeine (isometric)
Number of subjects: 14
Study: 26228448

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 8953

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 8953

Group type: EXPERIMENTAL
Intervention: Moderate chronic kidney disease
Number of subjects: 8953

Group type: EXPERIMENTAL
Intervention: Severe chronic kidney disease
Number of subjects: 8953

Group type: COMPARATOR
Intervention: Normal/mild chronic kidney disease
Number of subjects: 8953
Study: 24583931

Group type: EXPERIMENTAL
Intervention: Entecavir
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 22483479

Group type: EXPERIMENTAL
Intervention: Quinolone (QNL)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Rifampin (RFP)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Quinolone-conversion (QNL-C)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Rifampin-maintenance (RFP-M)
Number of subjects: 109
Study: 21355378

Group type: EXPERIMENTAL
Intervention: Temsirolimus (175 mg per week for 3 weeks, followed by 75 mg or 25 mg per week)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Temsirolimus (higher dose)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group (various other treatments)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Temsirolimus (both dose regimens)
Number of subjects: 162
Study: 17684084

Group type: EXPERIMENTAL
Intervention: Long-term ADT (≥6 months)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Short-term ADT (<6 months)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control subjects (no prostate cancer)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 100
Study: 15718193

Group type: EXPERIMENTAL
Intervention: Coping information about breast self-examinations
Number of subjects: 202

Group type: COMPARATOR
Intervention: Low-affirmation condition
Number of subjects: 202

Group type: COMPARATOR
Intervention: High-affirmation condition
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Previous exposure to breast cancer
Number of subjects: 202
Study: 14631055

Group type: EXPERIMENTAL
Intervention: Chest pain unit
Number of subjects: 972

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 972

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 972

Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 972

Group type: EXPERIMENTAL
Intervention: Indigestion or burning-type pain
Number of subjects: 972

Group type: EXPERIMENTAL
Intervention: Pain radiating to the left arm
Number of subjects: 972

Group type: EXPERIMENTAL
Intervention: Pain radiating to the right arm
Number of subjects: 972

Group type: EXPERIMENTAL
Intervention: Vomiting
Number of subjects: 972

Group type: EXPERIMENTAL
Intervention: Previous smoking
Number of subjects: 972

Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 972
Study: 10463902

Group type: EXPERIMENTAL
Intervention: Psychological treatments (specific details not provided)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinical practice guidelines based on evidence from randomised controlled trials
Number of subjects: 0
Study: 8680091

Group type: EXPERIMENTAL
Intervention: Navelbine and cisplatin (NVB-P)
Number of subjects: 612

Group type: COMPARATOR
Intervention: Vindesine and cisplatin (VDS-P)
Number of subjects: 612

Group type: COMPARATOR
Intervention: Navelbine alone (NVB)
Number of subjects: 612
Study: 1877960

Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0